Meta-Analysis of 21 Years of Alzheimer's Fluid Biomarker Research
Study improves confidence in three core biomarkers and five emerging markers, most in cerebrospinal fluid and one in blood.
6400 RESULTS
Sort By:
Study improves confidence in three core biomarkers and five emerging markers, most in cerebrospinal fluid and one in blood.
Thirteen “escapees” of childhood illness offer hope of finding protective variants that may pay dividends.
A NOVA special gets up close and personal with Alzheimer’s researchers and their patients, asking if this disease can be stopped.
Scientists report that the transcription factor NRF2 regulates tau expression, stimulating production of a protective isoform.
Neurogeneticists honored for their discoveries, especially of repeat expansions that cause ALS/FTD.
NAPA's latest collective exercise was a conference to update the field on progress in the past three years and advise the NIH on how to spend the next round of funds.
AD-Related Dementias Summit 2016: Progress, Aims, Dollars At 2016 Summit, Field Tackles AD-Related Dementias One By One Did you know the U.S. National Alzheimer’s Project Act covers Lewy body, frontotemporal, vascular, and mixed dementias, as well? It doe
A bit less strapped for funding, researchers are considering the next steps for Lewy body, frontotemporal, and vascular dementia.
At a workshop of the Frontotemporal Dementia Treatment Study Group, advocates and regulatory scientists urged leaders from industry and academia to forge a collaborative approach while the field is still young.
Hoping for better luck in clinical trials than their Alzheimer’s colleagues had in the past decade, FTD researchers are now chasing biomarkers. It’s slim pickings so far, but neurofilament, tau PET, and MRI are showing promise.
Drug Trials in Frontotemporal Dementia: Can Field Push Forward Together? WANTED: Biomarkers for Drug Trials in Frontotemporal Dementia Regulators Tell Frontotemporal Dementia Community: We Play on Your Team Earlier this month in Washington, D.C., 95 scien
Citing “fantastic opportunity,” FDA and EMA call for rigorous science. Agency scientists tell FTD Treatment Study Group: Explore individualized outcomes, and connect biomarkers to meaningful improvement.
C9ORF72 repeats create RNA foci and dipeptide aggregates in mice, but antisense oligonucleotides suppress them.
Backtracking of newly synthesized amyloid precursor protein from the Golgi to the ER facilitates APP modification and Aβ production.
Compared with previously published model lines, these animals develop more features of amyotrophic lateral sclerosis and frontotemporal dementia.